| abstract |
Disclosed herein are prolyl hydroxylase inhibitors capable of stabilizing hypoxia inducible factor-1 alpha (HIF-1α) as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Also further disclosed are methods for stimulating cellular immune responses in mammals, such as increasing phagocytosis, for example phagocytic cells, particularly keratinocytes, prolonging the neutrophil lifespan. Such disclosed compounds provide methods for treating diseases associated with the body's immune response. |